Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood (Journal of Neuro-Oncology, (2014), 10.1007/s11060-014-1428-z);Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood

Journal of Neuro-Oncology

Volumn 118, Issue 2, 2014, Pages 305-312

  Massimino, Maura ^a   Biassoni, Veronica ^a   Miceli, Rosalba ^a   Schiavello, Elisabetta ^a   Warmuth Metz, Monika ^c   Modena, Piergiorgio ^d   Casanova, Michela ^a   Pecori, Emilia ^a   Giangaspero, Felice ^e   Antonelli, Manila ^e   Buttarelli, Francesca Romana ^e   Potepan, Paolo ^a   Pollo, Bianca ^f   Nunziata, Raffaele ^f   Spreafico, Filippo ^a   Podda, Marta ^a   Anichini, Andrea ^a   Clerici, Carlo Alfredo ^a,b   Sardi, Iacopo ^g   De Cecco, Loris ^a   Bode, Udo ^h   Bach, Ferdinand ⁱ   Gandola, Lorenza ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Physiopathology Department State Medical School   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d SANT ANNA HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSITY OF BONN   (Germany)

ⁱ ONCOSCIENCE AG   (Germany)

Author keywords

Anti EGFR; DIPG; Nimotuzumab; Re irradiation; Target therapy

Indexed keywords

GADOLINIUM; NAVELBINE; NIMOTUZUMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VINBLASTINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IRON DEFICIENCY ANEMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PONTINE GLIOMA; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REPEAT PROCEDURE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR VOLUME; ANALOGS AND DERIVATIVES; BRAIN STEM NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; GLIOMA; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RETREATMENT; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN STEM NEOPLASMS; CHEMORADIOTHERAPY; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; RETREATMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84903899918     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-018-2893-6     Document Type: Erratum

References (38)

1. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ (1996) Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg 24:9-23
2. Donaldson SS, Laningham F, Fisher PG (2006) Advances toward an understanding of brainstem gliomas. J Clin Oncol 24:1266-1272
3. Massimino M, Spreafico F, Biassoni V et al (2008) Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 87:355-361
4. Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241-248
5. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ (2012) Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 38:27-35
6. Bode U, Massimino M, Bach F et al (2012) Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther. 12:1649-1659
7. Poussaint TY, Kocak M, Vajapeyam S et al (2011) MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol 13:417-427
8. Gilbertson RJ, Hill DA, Hernan R et al (2003) ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 9:3620-3624
9. Zarghooni M, Bartels U, Lee E et al (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337-1344
10. Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS (2012) Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol 14:326-332
11. Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251-253
12. Schwartzentruber J, Korshunov A, Liu XY et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-231
13. Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437
14. Ballester LY, Wang Z, Shandilya S et al (2013) Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas. Am J Surg Pathol 37:1357-1364
15. Massimino M, Bode U, Biassoni V, Fleischhack G (2011) Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 11:247-256
16. Dietil M. Scientifically based report on the blood-brain-barrier in malignant tumors. Expert Opinion - BBB - malignant brain tumors. BBB-09-11-16:1-9, Institute for Pathology, Charité-University Medicine Berlin
17. Fichtner I, Nowak CH. Report: biodistribution of nimotuzumab in xenografetd mice. Experimental Pharmacology & Oncology, Berlin-Buch gmbh, 22 April 2010
18. Crombet Ramos T, Figueredo J, Catala S et al (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 5:375-379
19. Hanley ML, Elion GB, Colvin OM et al (1998) Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother Pharmacol 42:479-482
20. Mouchard-Delmas C, Gourdier B, Vistelle R, Wiczewski M (1995) Modification of the blood-brain barrier permeability following intracarotid infusion of vinorelbine. Anticancer Res 15:2593-2596
21. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V (1989) In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(Suppl 4):5-8
22. Crinò L, Cappuzzo F, Zatloukal P et al (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253-4260
23. Depenbrock H, Shirvani A, Rastetter J, Hanauske AR (1995) Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Invest New Drugs 13:187-193
24. Tsai CM, Chiu CH, Chang KT et al (2012) Gefitinib enahances cytotoxicities of antimicrotubile agents in non-small cell lung cancer cells exhibiting no sensitizing epidermal growth factor mutation. J Thorac Oncol 7:1218-1227
25. Fontanilla HP, Pinnix CC, Ketonen LM et al (2012) Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 35:51-57
26. Fleischhack G, Siegler N, Zimmermann M, et al (2010) Concomitant therapy of nimotuzumab and standard radiotherapy for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. 14th international symposium of pediatric neuro-oncology, Vienna, Austria 20-23 June 2010 [abstract]. Neurooncology 12:ii8
27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
28. Casanova M, Ferrari A, Spreafico F et al (2002) Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 94:3263-3268
29. Geoerger B, Hargrave D, Thomas F et al (2011) Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 13:109-118
30. Pollack IF, Stewart CF, Kocak M et al (2011) A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 13:290-297
31. Broniscer A, Baker JN, Tagen M et al (2010) Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762-4768
32. Broniscer A, Baker SD, Wetmore C et al (2013) Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19:3050-3058
33. Lewis J, Lucraft H, Gholkar A (1997) UKCCSG study of accelerated radiotherapy for paediatric brain stem gliomas. United Kingdom Childhood Cancer Study Group. Int J Radiat Oncol Biol Phys 38:925-929
34. Janssens GO, Jansen MH, Lauwers SJ et al (2009) The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys 73:722-726
35. Negretti L, Bouchireb K, Levy-Piedbois C et al (2011) Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neurooncol 104:773-777
36. Sedlacik J, Winchell A, Kocak M, Loeffler RB, Broniscer A, Hillenbrand CM (2013) MR Imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. Am J Neuroradiol 34:1450-1455
37. Broniscer A, Laningham FH, Sanders RP, Kun LE, Ellison DW, Gajjar A (2008) Young age may predict a better outcome for children with diffuse pontine glioma. Cancer 113:566-572
38. Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S et al (2012) Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol 106:391-397